title: Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type.
abstract: OBJECTIVE
  MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues.
  
  
  METHODS
  We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed.
  
  
  RESULTS
  MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005).
  
  
  CONCLUSIONS
  The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.
authors.affiliation: Department of Human Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. east@m2.kufm.kagoshima-u.ac.jp
authors.forename: Michiyo
authors.initials: M
authors.lastname: Higashi
authors.forename: Norishige
authors.initials: N
authors.lastname: Yamada
authors.forename: Seiya
authors.initials: S
authors.lastname: Yokoyama
authors.forename: Sho
authors.initials: S
authors.lastname: Kitamoto
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tabata
authors.forename: Chihaya
authors.initials: C
authors.lastname: Koriyama
authors.forename: Surinder K
authors.initials: SK
authors.lastname: Batra
authors.forename: Suguru
authors.initials: S
authors.lastname: Yonezawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic / Q000378:metabolism; D018394:CA-125 Antigen / Q000378:metabolism*; D018281:Cholangiocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D005260:Female; D058851:GPI-Linked Proteins / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D000090204:Mesothelin; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism; D055262:Mucin-2 / Q000378:metabolism; D055264:Mucin-4 / Q000378:metabolism; D011379:Prognosis
chemical_list: D018394:CA-125 Antigen; D058851:GPI-Linked Proteins; C060192:MUC1 protein, human; C451759:MUC16 protein, human; C524625:MUC2 protein, human; C524658:MUC4 protein, human; D008565:Membrane Proteins; D018396:Mucin-1; D055262:Mucin-2; D055264:Mucin-4; D000090204:Mesothelin